Omeros (OMER) to Release Quarterly Earnings on Wednesday

Omeros (NASDAQ:OMER) is projected to issue its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.58) per share for the quarter. Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 4:30 PM ET.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.02. The company had revenue of $28.60 million for the quarter, compared to analysts’ expectations of $0.31 million. On average, analysts expect Omeros to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Omeros Stock Down 6.1%

Omeros stock opened at $6.73 on Wednesday. The company’s fifty day simple moving average is $5.36 and its 200-day simple moving average is $4.58. Omeros has a 12 month low of $2.95 and a 12 month high of $13.60. The stock has a market cap of $458.02 million, a P/E ratio of -3.19 and a beta of 2.32.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC acquired a new position in Omeros during the 1st quarter worth $357,000. B. Riley Wealth Advisors Inc. bought a new position in shares of Omeros during the 2nd quarter worth about $32,000. Tower Research Capital LLC TRC increased its holdings in shares of Omeros by 829.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 11,971 shares during the period. Sei Investments Co. bought a new position in shares of Omeros during the 2nd quarter worth about $40,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Omeros by 548.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 25,272 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 21,376 shares during the period. Institutional investors and hedge funds own 48.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Wall Street Zen raised shares of Omeros from a “sell” rating to a “hold” rating in a research note on Saturday, September 20th. HC Wainwright lifted their price objective on shares of Omeros from $9.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, October 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a research note on Wednesday, October 8th. WBB Securities reaffirmed a “strong-buy” rating and issued a $45.00 price objective on shares of Omeros in a research note on Wednesday, October 15th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research note on Wednesday, October 15th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.50.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.